deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02605837

A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved

Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study

Sponsor: Shire

Conditions Eosinophilic Esophagitis (EoE)
Interventions Oral Budesonide Suspension (OBS) Placebo
Updated 20 times since 2017 Last updated: Jan 30, 2025 Started: Dec 7, 2015 Primary completion: Jan 24, 2019 Completion: Feb 15, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Eosinophilic Esophagitis (EoE), this trial is completed. The trial is conducted by Shire and has accumulated 20 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Dec 2017 · 5 months · monthly snapshot~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~May 2018 · 3 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Oct 2018 · 3 months · monthly snapshot~Oct 2018 – ~Mar 2019 · 5 months · monthly snapshot~Mar 2019 – ~Sep 2019 · 6 months · monthly snapshot~Sep 2019 – ~Apr 2020 · 7 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jul 2024 · 34 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Mar 2025 — Sep 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Mar 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Sep 2021 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 15 earlier versions

  1. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE3

  2. Apr 2020 — Jan 2021 [monthly]

    Completed PHASE3

  3. Sep 2019 — Apr 2020 [monthly]

    Completed PHASE3

  4. Mar 2019 — Sep 2019 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Oct 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  6. Jul 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  7. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  8. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  9. Feb 2018 — May 2018 [monthly]

    Recruiting PHASE3

  10. Dec 2017 — Feb 2018 [monthly]

    Recruiting PHASE3

  11. Jul 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  12. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

  13. Apr 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  14. Feb 2017 — Apr 2017 [monthly]

    Recruiting PHASE3

  15. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shire
Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Asheville, United States , Atlanta, United States , Aurora, United States , Baton Rouge, United States , Birmingham, United States , Boston, United States , Bozeman, United States , Bristol, United States , Chapel Hill, United States and 57 more locations